Q1 conclude

cord and retina by administering the endogenous tripeptide EEP to a subject as a neuroprotectant or by administering EEP in combination with SPBN or other nitrone.

Page 7, replace paragraph 1, (lines 2-8) with the following:

Q2

The invention solves the above problems associated with known neuroprotectants by providing a neuroprotectant composition wherein the active ingredient is pGLU-GLU-PRO-NH^2 (EEP) or a combination of pGLU-GLU-PRO-NH_2 (EEP) and N-tert-Butyl-α-(2-sulfophenyl)nitrone (SPBN). The present invention is also directed to a method of treating and preventing diseases and injuries of the brain, spinal cord and retina by administering the endogenous tripeptide EEP to a subject as a neuroprotectant or by administering EEP in combination with SPBN or other nitrone.

Page 10, replace paragraph 3, (lines 20-22) with the following:

Q3

One aspect of the present invention relates to pharmaceutical compositions for the purposes set out above, in which the active ingredient is a compound EEP or also known as PGLU-GLU-PRO-NH_2.

Page 13, please replace lines 1-6 as follows:

Q4

Fold increase in EEP to 1mM resulted in almost doubling the neuroprotection: 38.9± 4.9% (n=8) in spinal neurons and 54.1 ± 5.3% (n=7) in neurons from forebrain (see Fig 1, Appendix III). Extending these observations, we compared the neuroprotective efficacy of EEP and TRH. We found that EEP was over three times as effective as TRH (see figs. 1 & 2, Appendix III).

IN THE CLAIMS:
Please cancel claims 2, 4, 6.

Please amend the claims as follows: